Early experience of thalidomide therapy for high-grade peripheral and facial arteriovenous malformations.

Autor:	Nip L; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Evans N; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Bali S; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Hopper C; Eastman Dental Institute, University College London, London, UK., Papadopoulou A; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Khalifa M; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Hamilton G; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK., Lim CS; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK - chunglim@nhs.net., Brookes J; Vascular Anomalies Center, Royal Free London NHS Foundation Trust, London, UK.
Jazyk:	angličtina
Zdroj:	International angiology : a journal of the International Union of Angiology [Int Angiol] 2023 Oct; Vol. 42 (5), pp. 448-456. Date of Electronic Publication: 2023 Nov 09.
DOI:	10.23736/S0392-9590.23.05111-8
Abstrakt:	Background: Arteriovenous malformations (AVMs) are developmental defects in the vascular system with abnormal connections between arteries and veins. A minority of AVMs are characterized by aggressive growth and continue to proliferate despite maximal surgical and interventional therapy. We report our outcomes with the use of thalidomide as the only UK specialist center adopting this novel approach for the management of AVMs refractory to conventional therapy. Methods: This was a retrospective case series which included only complex and proliferative AVM lesions (Schobinger grade III and IV). All patients prescribed thalidomide on a compassionate basis between September 2006 and August 2022 after attempts at embolosclerotherapy without satisfactory response were reviewed. Results: Eleven patients were included in our study. The median total duration of thalidomide use was 10 months. Two thirds of patients with pain (six of nine) reported an improvement, three quarters reported a reduction in swelling (six of eight) and all who presented with bleeding reported improvement in overall volume or frequency (four of four). Over the study period, 45% achieved a non-proliferative state with no further target vessel demonstrable on angiography. Mild, tolerable side effects such as fatigue were common (73%). There was only one major adverse reaction (neutropenia) necessitating cessation of therapy. Conclusions: We can conclude that thalidomide is able to reduce the symptom burden for patients with complex and proliferative AVMs that were refractory to established treatment modalities. Adverse effects are common, but the benefit achieved from taking thalidomide in otherwise treatment resistant cases outweighs the risks, most of which are manageable.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu